Meridian Bioscience (VIVO) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts VIVO Hot Sheet
Price: $1.60 --0%
Financial Fact:
INCOME TAX PROVISION: 3.26M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
INCOME TAX PROVISION: 3.26M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Meridian Bioscience (NASDAQ: VIVO) reported Q4 EPS of $0.14, in-line with the analyst estimate of $0.14. Revenue for the quarter came in at $47 million versus the consensus estimate of $47.7 million.Meridian Bioscience reaffirmed FY2017 guidance.
For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McDonald’s posts better-than-expected third-quarter comparable sales
- Peabody Energy (BTU) Misses Q3 EPS by 28c
- Neuronetics (STIM) Tops Q3 EPS by 7c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
